<DOC>
	<DOCNO>NCT01829178</DOCNO>
	<brief_summary>Cisplatin potent chemotherapeutic agent widely use treat many solid tumour . acute renal failure , despite conservative fluid electrolyte management , frequently report adverse event limit cisplatin use . Silymarin , flavonolignan complex isolate Silybum marianum , strong antioxidant , hepatoprotective , anticancer animal model nephroprotective property . Neutrophil gelatinase-associated lipocalin ( NGAL ) protein promise biomarker detect acute kidney injury due cisplatin . Milk thistle extract inhibitory effect epidermal growth factor receptor , vascular endothelial growth factor insulin-like growth factor-I show previous in-vitro studies.The aim present study , randomize double-blind placebo- control clinical trial , investigate therapeutic effect silymarin cisplatin induce nephrotoxicity 's impact chemotherapy . Fifty-eight patient diagnose upper gastrointestinal tract carcinoma randomize silymarin ( 420mg ) placebo plus chemotherapy [ cisplatin 50-60 mg/m2 , 5-fluorouracil mg/m2 , docetaxel 60-80 mg/m2 every 21 day ] 63 day inclusion . serum creatinin , blood urea nitrogen ( BUN ) , serum urine electrolyte measure daily chemotherapy . change urine NGAL , serum vascular endothelial growth factor ( VEGF ) caspase activity assess 64 day .</brief_summary>
	<brief_title>Evaluation Effects Silymarin Cisplatin Induced Nephrotoxicity Upper Gastrointestinal Adenocarcinoma</brief_title>
	<detailed_description>This study look possible protective effect silymarin kidney injury patient receive cisplatin .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>age &gt; 18 year diagnose measurable upper gastrointestinal adenocarcinoma swallow problem would like participate study Glomerular filtration rate ( GFR ) &gt; 45ml/min/1.73m2 end stage renal disease require dialysis post transplantation receive contrast medium last 72 hour chronic use corticosteroid chronic use angiotensinconverting enzyme inhibitor ( ACEI ) untreated hypoand hyperthyroidism ejection fraction &lt; 60 % active urinary tract infection iver disease ( five fold increase liver enzyme asymptomatic 3 fold increase symptomatic use nephrotoxic agent aminoglycoside , amphotericin karnofsky performance status &lt; 70</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>cisplatin</keyword>
	<keyword>nephrotoxicity</keyword>
	<keyword>antioxidant</keyword>
	<keyword>urine neutrophil gelatinase-associated lipocalin ( NGAL )</keyword>
</DOC>